Results 31 to 40 of about 425,308 (294)

A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan

Journal of Immunology Research, 2019
To improve efficacy and minimize toxicity of EGFR inhibition treatment, we developed Ame55, a novel anti-EGFR IgG1 with lower affinity to EGFR than cetuximab (C225) from a human phage library.
Weiyi Qiu, Chang Zhang, Shuang Wang, Xiaoyan Yu, Qiong Wang, Dadi Zeng, Peng Du, Jinling Ma, Yiqiong Zheng, Bo Pang, Yunzhou Yu, Feng Long, Xiaobin Pang, Zhiwei Sun   +13 more
doaj   +1 more source

Engineering Synthetic Antibody by Expanded Genetic Code [PDF]

, 2017
Antibodies are extensively used in research for diagnostic and therapeutic purposes because of their unrivaled specificity and biomarker binding strengths.1 Currently, monoclonal antibodies are most commonly used because of their production consistency ...
Batiuk, Elizabeth, Kiyohara, Casey, Nguyen, Tracy   +2 more
core   +1 more source

Engineering antibody therapeutics

Current Opinion in Structural Biology, 2016
The successful introduction of antibody-based protein therapeutics into the arsenal of treatments for patients has within a few decades fostered intense innovation in the production and engineering of antibodies. Reviewed here are the methods currently used to produce antibodies along with how our knowledge of the structural and functional ...
Chiu, Mark L, Gilliland, Gary L
openaire   +2 more sources

Therapeutic Apheresis for Intravenous Methylprednisolone‐Refractory Neuromyelitis Optica Spectrum Disorder: Clinical and Radiological Outcomes in a Single‐Center Case Series

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune disease of the central nervous system. High‐dose intravenous methylprednisolone (IVMP) is the standard first‐line therapy for acute attacks, although some patients remain refractory.
Wataru Horiguchi, Daisuke Katagiri, Takeyuki Watadani, Shunichi Matsuda, Hiroshi Kaneko, Noritoshi Arai   +5 more
wiley   +1 more source

ipRGCs Sensitive Blue Light Exposure Promotes the Robustness of Circadian and Neural Stem Cells in Sleep Deprived Conditions

Stem Cells International
Circadian rhythm abnormalities due to sleep deprivation (SD) may promote the development of emotional and cognitive disorders. Though light therapies have been employed to treat circadian disorders, the exact treatments and their underlying biology are ...
Zhaoting Bu, Xiaotong Li, Jinyu Shi, Qiaozhen Qin, Heyang Zhang, Yuanrong Qiu, Lingyu Zhang, Yifei Tan, Hanping Shi, Xiaoxia Jiang   +9 more
doaj   +1 more source

Tetanus Neurotoxin Neutralizing Antibodies Screened from a Human Immune scFv Antibody Phage Display Library

Toxins, 2016
Tetanus neurotoxin (TeNT) produced by Clostridium tetani is one of the most poisonous protein substances. Neutralizing antibodies against TeNT can effectively prevent and cure toxicosis.
Han Wang, Rui Yu, Ting Fang, Ting Yu, Xiangyang Chi, Xiaopeng Zhang, Shuling Liu, Ling Fu, Changming Yu, Wei Chen   +9 more
doaj   +1 more source

Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco [PDF]

, 2014
The proposed clinical trial in Africa of VRC01, a potent broadly neutralizing antibody (bNAb) capable of neutralizing 91% of known HIV-1 isolates, raises concerns about testing a treatment which will be too expensive to be accessible by the most ...
EMEA, Montefiori D.C., Pabst M., Pegu A., WHO   +4 more
core   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer

Journal of Experimental & Clinical Cancer Research, 2020
Background Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown to be safe but with poor efficacy.
Yuexian Zhou, Huifang Zong, Lei Han, Yueqing Xie, Hua Jiang, John Gilly, Baohong Zhang, Huili Lu, Jie Chen, Rui Sun, Zhidi Pan, Jianwei Zhu   +11 more
doaj   +1 more source

Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV

Frontiers in Cellular and Infection Microbiology, 2023
Nipah virus (NiV) and Hendra virus (HeV) are newly emerging dangerous zoonotic pathogens of the Henipavirus genus of the Paramyxoviridae family. NiV and HeV (HNVs) which are transmitted by bats cause acute respiratory disease and fatal encephalitis in ...
Xiaoyan Huang, Xiaoyan Huang, Yaohui Li, Ruihua Li, Shaoyan Wang, Lu Yang, Lu Yang, Shuyi Wang, Ying Yin, Xiaodong Zai, Jun Zhang, Junjie Xu   +11 more
doaj   +1 more source